Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Optimi Health (OPTI) is continuing to advance construction of its mushroom research and production facility in Princeton, British Columbia
  • Current estimates place the project as between three to four weeks behind schedule
  • Construction of the two adjacent 10,000 square foot facilities originally began in August of 2020
  • The company also recently received notification regarding its application for a Controlled Substance Dealers License
  • Optimi Health is down 3.08 per cent, trading at $0.63 at 1:29 pm ET

Optimi Health (OPTI) is continuing to advance construction of its mushroom research and production facility in Princeton, British Columbia.

Current estimates place the project as between three to four weeks behind schedule.

Construction of the two adjacent 10,000 square foot facilities originally began in August of 2020.

The Vancouver-based functional mushroom company considers the delay to be acceptable, “against the backdrop of the ongoing global health crisis.”

Final build-out of both buildings is continuing.

The company also recently received notification regarding its application for a Controlled Substance Dealers License. The license specifically references the facility details for both proposed Security Level 8 and grow room installations.

The review indicated the proposed security environs may meet the requirements of the Health Canada Directive on Physical Security Requirements for Controlled Substances and Drugs Containing Cannabis if built as proposed.

The notification officially advised Optimi it may begin construction of these secure elements of the facility and further requested notification upon completion in order to arrange for an inspection.

In accordance with Health Canada protocols, now that Optimi has been advised to proceed with Security Level 8 construction, secure vault ceiling decking will be installed immediately in preparation for a planned concrete pour.

“The pace of activity has been phenomenal with updates occurring daily. We are delighted how well everything is coming together, and the quality of work continues to be excellent. I look forward to delivering this project within a timeline and budget that’s not far from our original pre-Covid expectations, and under the extraordinary circumstances are very pleased with how diligently the entire team is working to get Canada’s first all-natural end-to-end mushroom facility ready for production. It’s shaping up to be a fabulous world-class facility we can all be justifiably proud of,” said Optimi Health COO and Director, Bryan Safarik.

Optimi is developing a sophisticated mushroom brand that focuses on the health and wellness markets.

Optimi Health is down 3.08 per cent, trading at $0.63 at 1:29 pm ET.

More From The Market Herald
Small Pharma - CEO, Peter Rands.

" Small Pharma (TSXV:DMT) granted European patent

Small Pharma (DMT) has been granted a European patent, strengthening its ketamine-based patent portfolio.

" Levitee Labs (CSE:LVT) enters into credit facility for up to $12 Million

Levitee Labs Inc. (LVT) has entered into a financing agreement for up to $12 million to fund further business expansion.
Small Pharma - Chief Medical and Scientific Officer, Carol Routledge.

" Small Pharma (TSXV:DMT) granted fast-track designation for DMT-assisted therapy

Small Pharma (DMT) has been granted fast-track designation in the U.K. for DMT-assisted therapy for major depressive disorder.

" Psyched Wellness (CSE:PSYC) shares preliminary data from amanita muscaria mushroom study

Psyched Wellness Ltd. (PSYC) has released its preliminary data revealing a potential new functional property and health benefit of AME-1.